% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Krackhardt:132720,
author = {A. M. Krackhardt$^*$ and B. Anliker and M. Hildebrandt$^*$
and M. Bachmann$^*$ and S. Eichmüller$^*$ and D.
Nettelbeck$^*$ and M. Renner and L. Uharek$^*$ and G.
Willimsky$^*$ and M. Schmitt$^*$ and W. S. Wels$^*$ and M.
Schüssler-Lenz},
title = {{C}linical translation and regulatory aspects of
{CAR}/{TCR}-based adoptive cell therapies-the {G}erman
{C}ancer {C}onsortium approach.},
journal = {Cancer immunology immunotherapy},
volume = {67},
number = {4},
issn = {1432-0851},
address = {Berlin},
publisher = {Springer},
reportid = {DKFZ-2018-00374},
pages = {513 - 523},
year = {2018},
abstract = {Adoptive transfer of T cells genetically modified by TCRs
or CARs represents a highly attractive novel therapeutic
strategy to treat malignant diseases. Various approaches for
the development of such gene therapy medicinal products
(GTMPs) have been initiated by scientists in recent years.
To date, however, the number of clinical trials commenced in
Germany and Europe is still low. Several hurdles may
contribute to the delay in clinical translation of these
therapeutic innovations including the significant complexity
of manufacture and non-clinical testing of these novel
medicinal products, the limited knowledge about the
intricate regulatory requirements of the academic developers
as well as limitations of funds for clinical testing. A
suitable good manufacturing practice (GMP) environment is a
key prerequisite and platform for the development,
validation, and manufacture of such cell-based therapies,
but may also represent a bottleneck for clinical
translation. The German Cancer Consortium (DKTK) and the
Paul-Ehrlich-Institut (PEI) have initiated joint efforts of
researchers and regulators to facilitate and advance early
phase, academia-driven clinical trials. Starting with a
workshop held in 2016, stakeholders from academia and
regulatory authorities in Germany have entered into
continuing discussions on a diversity of scientific,
manufacturing, and regulatory aspects, as well as the
benefits and risks of clinical application of CAR/TCR-based
cell therapies. This review summarizes the current state of
discussions of this cooperative approach providing a basis
for further policy-making and suitable modification of
processes.},
subtyp = {Review Article},
cin = {L701 / G182 / L301 / L101 / L201 / L501},
ddc = {610},
cid = {I:(DE-He78)L701-20160331 / I:(DE-He78)G182-20160331 /
I:(DE-He78)L301-20160331 / I:(DE-He78)L101-20160331 /
I:(DE-He78)L201-20160331 / I:(DE-He78)L501-20160331},
pnm = {317 - Translational cancer research (POF3-317)},
pid = {G:(DE-HGF)POF3-317},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:29380009},
doi = {10.1007/s00262-018-2119-y},
url = {https://inrepo02.dkfz.de/record/132720},
}